Literature DB >> 34244156

Incidence and Mortality of Cancers of the Biliary Tract, Gallbladder, and Liver by Sex, Age, Race/Ethnicity, and Stage at Diagnosis: United States, 2013 to 2017.

Taylor D Ellington1,2, Behnoosh Momin2, Reda J Wilson2, S Jane Henley2, Manxia Wu2, A Blythe Ryerson3.   

Abstract

BACKGROUND: Few population-based studies have examined incidence and mortality of cancers of the biliary tract, including intrahepatic bile duct, extrahepatic bile duct, ampulla of Vater, and overlapping or other lesions of the biliary tract in one study.
METHODS: To further the understanding of recent rates of biliary tract cancers, we used population-based data, to examine incidence and mortality during 2013 to 2017. We examined how rates varied by sex, age, race/ethnicity, U.S. census region, and stage at diagnosis.
RESULTS: Intrahepatic bile duct was the most common biliary tract cancer, with an incidence rate of 1.49 per 100,000 persons. Cancer incidence rates per 100,000 persons were 0.96 for extrahepatic bile duct, 0.45 for ampulla of Vater, and 0.24 for overlapping or other lesions of the biliary tract. Cancer death rates per 100,000 persons were 1.66 for intrahepatic bile duct and 0.45 for other biliary tract. Intrahepatic bile duct incidence and death rates were higher among males than females, higher among Hispanic and Asian and Pacific Islander persons compared with non-Hispanic Whites, and higher in the Northeast and in urban counties.
CONCLUSIONS: This report provides national estimates of these rare biliary tract cancers. IMPACT: Key interventions targeted to high-risk populations may help reduce incidence and mortality of cancers of the biliary tract by improving primary prevention through strategies to reduce tobacco and alcohol use, control overweight and obesity, and promote hepatitis B vaccination and use of syringe service programs meant to curb the transmission of infectious diseases such as viral hepatitis. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2021        PMID: 34244156      PMCID: PMC9351546          DOI: 10.1158/1055-9965.EPI-21-0265

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.090


  30 in total

1.  International statistical classification of diseases and related health problems. Tenth revision.

Authors:  G R Brämer
Journal:  World Health Stat Q       Date:  1988

Review 2.  Gallbladder cancer: epidemiology and genetic risk associations.

Authors:  Mikayla A Schmidt; Lorena Marcano-Bonilla; Lewis R Roberts
Journal:  Chin Clin Oncol       Date:  2019-08

Review 3.  Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.

Authors:  Omar Massoud; Michael Charlton
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

4.  Screening for Hepatitis B Virus Infection in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement.

Authors:  Alex H Krist; Karina W Davidson; Carol M Mangione; Michael J Barry; Michael Cabana; Aaron B Caughey; Katrina Donahue; Chyke A Doubeni; John W Epling; Martha Kubik; Gbenga Ogedegbe; Douglas K Owens; Lori Pbert; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong
Journal:  JAMA       Date:  2020-12-15       Impact factor: 56.272

5.  Gallbladder Cancer Incidence and Mortality, United States 1999-2011.

Authors:  S Jane Henley; Hannah K Weir; Melissa A Jim; Meg Watson; Lisa C Richardson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-06-12       Impact factor: 4.254

6.  Incidence, diagnosis, and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Authors:  Johan Fevery; Chris Verslype; Gillian Lai; Raymond Aerts; Werner Van Steenbergen
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

7.  Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States.

Authors:  Farhad Islami; Ann Goding Sauer; Kimberly D Miller; Rebecca L Siegel; Stacey A Fedewa; Eric J Jacobs; Marjorie L McCullough; Alpa V Patel; Jiemin Ma; Isabelle Soerjomataram; W Dana Flanders; Otis W Brawley; Susan M Gapstur; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-11-21       Impact factor: 508.702

8.  Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012.

Authors:  Theodore R Holford; Rafael Meza; Kenneth E Warner; Clare Meernik; Jihyoun Jeon; Suresh H Moolgavkar; David T Levy
Journal:  JAMA       Date:  2014-01-08       Impact factor: 157.335

9.  Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018.

Authors:  A Blythe Ryerson; Sarah Schillie; Laurie K Barker; Benjamin A Kupronis; Carolyn Wester
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-10       Impact factor: 17.586

10.  Vital Signs: Trends in Incidence of Cancers Associated with Overweight and Obesity - United States, 2005-2014.

Authors:  C Brooke Steele; Cheryll C Thomas; S Jane Henley; Greta M Massetti; Deborah A Galuska; Tanya Agurs-Collins; Mary Puckett; Lisa C Richardson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-10-03       Impact factor: 17.586

View more
  2 in total

Review 1.  Evolving Paradigms in the Systemic Treatment of Advanced Gallbladder Cancer: Updates in Year 2022.

Authors:  Zishuo Ian Hu; Kian-Huat Lim
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

2.  Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017.

Authors:  Milind Javle; Sunyoung Lee; Nilofer S Azad; Mitesh J Borad; Robin Kate Kelley; Smitha Sivaraman; Anna Teschemaker; Ishveen Chopra; Nora Janjan; Shreekant Parasuraman; Tanios S Bekaii-Saab
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.